• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by AtaiBeckley Inc.

    7/17/26 5:17:47 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    AtaiBeckley Inc.

    (Name of Issuer)


    Common stock, par value $0.01 per share

    (Title of Class of Securities)




    04650F101

    (CUSIP Number)
    Evan S. Simpson
    1 New Fetter Lane,
    London, X0, EC4A 1AN
    44 20 7959-8426

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    07/15/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    04650F101


    1 Name of reporting person

    Apeiron Investment Group Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    MALTA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    55,770,948.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    55,770,948.00
    11Aggregate amount beneficially owned by each reporting person

    55,770,948.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    15.1 %
    14Type of Reporting Person (See Instructions)

    CO



    SCHEDULE 13D

    CUSIP Number(s):
    04650F101


    1 Name of reporting person

    Apeiron Presight Capital Fund II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,799,302.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,799,302.00
    11Aggregate amount beneficially owned by each reporting person

    1,799,302.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP Number(s):
    04650F101


    1 Name of reporting person

    Presight Capital Management I, L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,799,302.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,799,302.00
    11Aggregate amount beneficially owned by each reporting person

    1,799,302.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.5 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP Number(s):
    04650F101


    1 Name of reporting person

    Fabian Hansen
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,799,302.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,799,302.00
    11Aggregate amount beneficially owned by each reporting person

    1,799,302.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    04650F101


    1 Name of reporting person

    Christian Angermayer
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,600,418.00
    8Shared Voting Power

    56,812,134.00
    9Sole Dispositive Power

    1,600,418.00
    10Shared Dispositive Power

    56,812,134.00
    11Aggregate amount beneficially owned by each reporting person

    56,812,134.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    15.4 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common stock, par value $0.01 per share
    (b)Name of Issuer:

    AtaiBeckley Inc.
    (c)Address of Issuer's Principal Executive Offices:

    250 West 34th Street, New York, NEW YORK , 10119.
    Item 2.Identity and Background
    (a)
    This Amendment No. 4 (the "Amendment No. 4") to Schedule 13D amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on February 24, 2025 (the "Schedule 13D"), Amendment No. 1 thereto filed on June 4, 2025, Amendment No. 2 thereto filed on August 18, 2025 and Amendment No. 3 thereto filed on October 20, 2025. This Amendment No. 4 is filed by: (i) Apeiron Investment Group Ltd. ("Apeiron"); (ii) Apeiron Presight Capital Fund II, L.P. ("Presight II"); (iii) Presight Capital Management I, L.L.C. ("Presight Management"); (iv) Fabian Hansen; and (v) Christian Angermayer.
    (b)
    The principal business address of Apeiron and Mr. Angermayer is 66 & 67 Amery Street, SLM1707, Sliema, Malta. The principal business address of each of the remaining Reporting Persons is 440 N Barranca Ave #3391, Covina, CA 91723 USA.
    (c)
    The principal business of Apeiron and Presight II are making investments. The principal business of Presight Management is acting as the general partner of Presight II. Apeiron's sole director is Sanad Abushala and his principal business address is Centris Business Gateway, Level 0/C, Triq Is-Salib tal-Imriehel, Zone 3, Central Business District, Mirehel, Birkirkara, Malta CBD 3020. His present principal occupation is Head of Treasury at Apeiron.
    (d)
    No
    (e)
    No
    (f)
    Presight II and Presight Management are organized under the laws of the state of Delaware. Apeiron is organized under the laws of the Malta. Each of Messrs. Hansen and Angermayer is a German citizen. Mr. Abushala is a Croatian citizen.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: On July 15, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to satisfaction or waiver of the conditions therein, Merger Sub will merge with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Parent. On July 15, 2026, in connection with the execution of the Merger Agreement, Apeiron and Christian Angermeyer entered into separate Voting and Support Agreements (the "Support Agreements") with Parent. The Support Agreements provide that, among other things, each of Apeiron and Christian Angermeyer has agreed (i) to vote all of the shares of common stock held by such stockholder in favor of the adoption of the Merger Agreement, subject to certain exceptions (including the valid termination of the Merger Agreement), (ii) not to transfer such shares of common stock, and (iii) to certain other restrictions on its ability to take actions with respect to the Company and its shares of common stock. The foregoing descriptions of the Support Agreements does not purport to be complete and is qualified in its entirety by the full text of the form of Support Agreement, a copy of which is filed as Exhibit 99.1 to this Amendment No. 4 and is incorporated into this Item 4 by reference. A copy of the form of Support Agreement and the above description of the Support Agreements have been included to provide investors with information regarding the terms of the Support Agreements. They are not intended to provide any other factual information about the parties to the Support Agreements or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Support Agreements were made only for the purposes of the Support Agreements and as of specific dates, are solely for the benefit of the parties to the Support Agreements, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Support Agreements instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Support Agreements and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Support Agreements, which subsequent information may or may not be fully reflected in the Reporting Persons', the Issuer's or Parent's public disclosures.
    Item 5.Interest in Securities of the Issuer
    (a)
    As of June 22, 2026, the Reporting Persons collectively beneficially own 56,812,134 shares of common stock, representing approximately 15.4% of the voting rights attached to the shares of common stock. The ownership percentages set forth in this Amendment No. 4 have been calculated on the basis of 368,166,674 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on May 12, 2026.
    (b)
    The following table sets forth, as of the date of this Amendment No. 4, the aggregate number of shares of common stock and percentage of shares of common stock beneficially owned by each of the Reporting Persons, as well as the number of shares of common stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of. Reporting Amount beneficially Percent of Sole power to vote or Shared power to vote or Sole power to dispose or Shared power to dispose or Person owned class to direct the vote to direct the vote to direct the disposition to direct the disposition Apeiron Investment 55,770,948 15.1% 0 55,770,948 0 55,770,948 Group, Ltd. Apeiron Presight 1,799,302 0.5% 0 1,799,302 0 1,799,302 Capital Fund II, L.P. Presight Capital 1,799,302 0.5% 0 1,799,302 0 1,799,302 Management I, L.L.C. Fabian Hansen 1,799,302 0.5% 0 1,799,302 0 1,799,302 Christian Angermayer 56,812,134 15.4% 1,600,418 56,812,134 1,600,418 56,812,134 Presight II is the record holder of 1,799,302 shares of common stock. Apeiron is the record holder of 53,917,646 shares of common stock. Christian Angermayer may be deemed to beneficially own 1,041,186 shares of common stock underlying vested options to purchase shares of common stock. Presight Management is the general partner of Presight II. Apeiron and Fabian Hansen are the managing members of Presight Management. Christian Angermayer is the controlling shareholder of Apeiron. As a result, each of Presight Management, Apeiron, Mr. Hansen and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Presight II, and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Apeiron.
    (c)
    Except as described in this Item 5, none of the Reporting Persons has beneficial ownership of any shares of common stock or, except as described in this Schedule 13D, has effected any transaction in the shares of common stock during the past 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock owned, directly or indirectly, by the Reporting Persons.
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The information provided and/or incorporated by reference in Item 4 is hereby incorporated by reference into this Item 6.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit No. Description Exhibit 99.1 Form of Voting and Support Agreement, dated as of July 15, 2026 (incorporated by reference to Exhibit 10.1 of the Issuer's Current Report on Form 8-K, filed on July 16, 2026).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Apeiron Investment Group Ltd.
     
    Signature:/s/ Sanad Abushala
    Name/Title:Sanad Abushala, Director
    Date:07/17/2026
     
    Apeiron Presight Capital Fund II, L.P.
     
    Signature:/s/ Fabian Hansen
    Name/Title:Fabian Hansen, Managing Member
    Date:07/17/2026
     
    Presight Capital Management I, L.L.C.
     
    Signature:/s/ Fabian Hansen
    Name/Title:Fabian Hansen, Managing Member
    Date:07/17/2026
     
    Fabian Hansen
     
    Signature:/s/ Fabian Hansen
    Name/Title:Fabian Hansen
    Date:07/17/2026
     
    Christian Angermayer
     
    Signature:/s/ Christian Angermeyer
    Name/Title:Christian Angermayer
    Date:07/17/2026
    Get the next $ATAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    3/27/2026$12.00Buy
    Deutsche Bank
    1/20/2026$11.00Buy
    Guggenheim
    10/13/2025$12.00Buy
    Needham
    7/29/2025$14.00Outperform
    Oppenheimer
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    More analyst ratings

    $ATAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by AtaiBeckley Inc.

    SCHEDULE 13D/A - AtaiBeckley Inc. (0002081043) (Subject)

    7/17/26 5:17:47 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by AtaiBeckley Inc.

    DEFA14A - AtaiBeckley Inc. (0002081043) (Filer)

    7/16/26 4:01:23 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by AtaiBeckley Inc.

    DEFA14A - AtaiBeckley Inc. (0002081043) (Filer)

    7/16/26 4:01:25 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

    Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso

    7/21/26 8:30:00 AM ET
    $ATAI
    $CMPS
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

    Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in

    7/17/26 8:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

    AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a discovery pipeline of next-generation compounds

    7/16/26 6:45:00 AM ET
    $LLY
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hershberg Robert exercised 100,000 shares at a strike of $1.35 and sold $496,000 worth of shares (100,000 units at $4.96) as part of a pre-agreed trading plan (SEC Form 4)

    4 - AtaiBeckley Inc. (0002081043) (Issuer)

    7/9/26 5:30:27 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Craig Kevin James exercised 42,579 shares at a strike of $1.43 and sold $192,031 worth of shares (42,579 units at $4.51) as part of a pre-agreed trading plan (SEC Form 4)

    4 - AtaiBeckley Inc. (0002081043) (Issuer)

    6/29/26 6:00:39 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Kochendoerfer Gerd exercised 50,000 shares at a strike of $1.60 and sold $250,000 worth of shares (50,000 units at $5.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - AtaiBeckley Inc. (0002081043) (Issuer)

    6/29/26 6:00:30 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on AtaiBeckley with a new price target

    Deutsche Bank initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $12.00

    3/27/26 8:46:10 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on AtaiBeckley with a new price target

    Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00

    1/20/26 9:22:21 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

    AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitutionThe Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarkedInclusion expands AtaiBeckley’s visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be ad

    6/25/26 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

    - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

    1/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

    EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges' g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behavio

    2/26/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    5/3/24 4:06:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    3/12/24 9:30:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care